High-mobility group box 1 (HMGB-1) is a nuclear protein physiologically involved in the maintaining of DNA structure in the nucleus. When tissue damage occurs, necrotic cells as well as inflammatory cells, once activated, release this protein in circulating blood, where it seems to exert a direct proinflammatory action. Thus, HMGB-1 might be involved in the pathophysiology of several diseases, including cardiovascular disease. However, the experimental evidence has not yet clarified its cardiovascular role which is still debated. Specifically, it is still not completely resolved whether HMGB-1 plays a protective or detrimental role on cardiovascular function. In this review, we consider the role of HMGB-1 in pathological conditions and comment on the role of this protein in the cardiovascular disease.
DaubertMAJeremiasA. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010;6:691–699.
2.
MatzingerP. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305.
3.
ShawTJMartinP. Wound repair at a glance. J Cell Sci. 2009;122(Pt 18):3209–3213.
4.
HockRFurusawaTUedaTBustinM. HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007;17(2):72–79.
5.
ScaffidiPMisteliTBianchiME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.
6.
SessaLBianchiME. The evolution of High Mobility Group Box (HMGB) chromatin proteins in multicellular animals. Gene. 2007;387(1-2):133–140.
7.
BustinMNeihartNK. Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell. 1979;16(1):181–189.
8.
KuehlLSalmondBTranL. Concentrations of high-mobility-group proteins in the nucleus and cytoplasm of several rat tissues. J Cell Biol. 1984;99(2):648–654.
9.
MosevitskyMINovitskayaVAIogannsenMGZabezhinskyMA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem. 1989;185(2):303–310.
10.
BustinM. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci. 2001;26(3):152–153.
11.
StrosM. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010;1799(1-2):101–113.
12.
GerlitzGHockRUedaTBustinM. The dynamics of HMG protein-chromatin interactions in living cells. Biochem Cell Biol. 2009;87(1):127–137.
13.
CatenaREscoffierECaronCKhochbinSMartianovIDavidsonI. HMGB4, a novel member of the HMGB family, is preferentially expressed in the mouse testis and localizes to the basal pole of elongating spermatids. Biol Reprod. 2009;80(2):358–366.
14.
YamadaSYakabeKIshiiJImaizumiHMaruyamaI. New high mobility group box 1 assay system. Clin Chim Acta. 2006;372(1-2):173–178.
15.
RauvalaHMerenmiesJPihlaskariRKorkolainenMHuhtalaMLPanulaP. The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol. 1988;107(6 Pt 1):2293–2305.
16.
NairSMJungalwalaFB. Characterization of a sulfoglucuronyl carbohydrate binding protein in the developing nervous system. J Neurochem. 1997;68(3):1286–1297.
17.
YamadaSMaruyamaI. HMGB1, a novel inflammatory cytokine. Clin Chim Acta. 2007;375(1-2):36–42.
18.
RouhiainenAImaiSRauvalaHParkkinenJ. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000;84(6):1087–1094.
19.
SimsGPRoweDCRietdijkSTHerbstRCoyleAJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–388.
20.
CastiglioniACantiVRovere-QueriniPManfrediAA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res. 2011;343(1):189–199.
21.
WeirHMKraulisPJHillCSRaineARLaueEDThomasJO. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12(4):1311–1319.
22.
HardmanCHBroadhurstRWRaineARGrasserKDThomasJOLaueED. Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry. 1995;34(51):16596–16607.
23.
SheflinLGFucileNWSpauldingSW. The specific interactions of HMG 1 and 2 with negatively supercoiled DNA are modulated by their acidic C-terminal domains and involve cysteine residues in their HMG 1/2 boxes. Biochemistry. 1993;32(13):3238–3248.
24.
StrosMStokrovaJThomasJO. DNA looping by the HMG-box domains of HMG1 and modulation of DNA binding by the acidic C-terminal domain. Nucleic Acids Res. 1994;22(6):1044–1051.
25.
TeoSHGrasserKDThomasJO. Differences in the DNA-binding properties of the HMG-box domains of HMG1 and the sex-determining factor SRY. Eur J Biochem. 1995;230(3):943–950.
26.
StrosM.DNA bending by the chromosomal protein HMG1 and its high mobility group box domains. Effect of flanking sequences. J Biol Chem. 1998;273(17):10355–10361.
27.
PaullTTHaykinsonMJJohnsonRC. The nonspecific DNA-binding and -bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures. Genes Dev. 1993;7(8):1521–1534.
28.
PayetDTraversA. The acidic tail of the high mobility group protein HMG-D modulates the structural selectivity of DNA binding. J Mol Biol. 1997;266(1):66–75.
29.
RittCGrimmRFernandezSAlonsoJCGrasserKD. Basic and acidic regions flanking the HMG domain of maize HMGa modulate the interactions with DNA and the self-association of the protein. Biochemistry. 1998;37(8):2673–2681.
30.
PenzoMMolteniRSudaT. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol. 2010;184(8):4497–4509.
31.
YoshiokaKSaitoKTanabeT. Differences in DNA recognition and conformational change activity between boxes A and B in HMG2 protein. Biochemistry. 1999;38(2):589–595.
32.
GrasserKDTeoSHLeeKB. DNA-binding properties of the tandem HMG boxes of high-mobility-group protein 1 (HMG1). Eur J Biochem. 1998;253(3):787–795.
33.
IsacksonPJFishbackJLBidneyDLReeckGR. Preferential affinity of high molecular weight high mobility group non-histone chromatin proteins for single-stranded DNA. J Biol Chem. 1979;254(13):5569–5572.
34.
BianchiMEBeltrameMPaonessaG. Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989;243(4894 Pt 1):1056–1059.
35.
HamadaHBustinM. Hierarchy of binding sites for chromosomal proteins HMG 1 and 2 in supercoiled deoxyribonucleic acid. Biochemistry.1985;24(6):1428–1433.
36.
CatoLStottKWatsonMThomasJO. The interaction of HMGB1 and linker histones occurs through their acidic and basic tails. J Mol Biol. 2008;384(5):1262–1272.
37.
ZhangQWangY. High mobility group proteins and their post-translational modifications. Biochim Biophys Acta. 2008;1784(9):1159–1166.
38.
BonaldiTTalamoFScaffidiP. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551–5560.
39.
YounJHShinJS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177(11):7889–7897.
40.
ItoIFukazawaJYoshidaM. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem. 2007;282(22):16336–16344.
41.
DitsworthDZongWXThompsonCB. Activation of poly (ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem. 2007;282(24):17845–17854.
42.
HarrisHERaucciA. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006;7(8):774–778.
43.
FoellDWittkowskiHRothJ. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007;3(7):382–390.
FoellDWittkowskiHVoglTRothJ. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81(1):28–37.
46.
HalleAHornungVPetzoldGC. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857–865.
MartinonFMayorATschoppJ. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–265.
49.
CayrolCGirardJP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021–9026.
50.
HaraldsenGBaloghJPollheimerJSponheimJKuchlerAM. Interleukin-33 - cytokine of dual function or novel alarmin?Trends Immunol. 2009;30(5):227–233.
51.
WangHBloomOZhangM. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251.
52.
Rendon-MitchellBOchaniMLiJ. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol. 2003;170(7):3890–3897.
53.
UlloaLOchaniMYangH. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002;99(19):12351–12356.
54.
BellCWJiangWReichCF 3rdPisetskyDS.The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006;291(6):C1318–1C325.
55.
JiangWBellCWPisetskyDS. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol. 2007;178(10):6495–6503.
56.
KazamaHRicciJEHerndonJMHoppeGGreenDRFergusonTA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008;29(1):21–32.
57.
HreggvidsdottirHSLundbergAMAvebergerACKlevenvallLAnderssonUHarrisHE. HMGB1-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med. 2011.
58.
CirilloPGiallauriaFPacileoM. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. J Card Fail. 2009;15(4):362–367.
59.
AnderssonUTraceyKJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–162.
60.
ArumugamTVOkunETangSCThundyilJTaylorSMWoodruffTM. Toll-like receptors in ischemia-reperfusion injury. Shock. 2009;32(1):4–16.
YangQWXiangJZhouYZhongQLiJC. Targeting HMGB1/TLR4 signaling as a novel approach to treatment of cerebral ischemia. Front Biosci (Schol Ed). 2010;2:1081–1091.
63.
ParkJSSvetkauskaiteDHeQ. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279(9):7370–7377.
64.
KawaiTAkiraS. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384.
65.
van ZoelenMAYangHFlorquinS. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock. 2009;31(3):280–284.
66.
YangHHreggvidsdottirHSPalmbladK. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107(26):11942–11947.
67.
YangJChenLDingJRongHDongWLiX. High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep. 2011;39(3):3361–3367.
68.
SchmidtAMYanSDYanSFSternDM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949–955.
69.
NeeperMSchmidtAMBrettJ. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998–15004.
70.
SchmidtAMYanSDYanSFSternDM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498(2-3):99–111.
71.
GuimaraesELEmpsenCGeertsAvan GrunsvenLA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 2010;52(3):389–397.
72.
HofmannMADrurySFuC. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889–901.
73.
ToureFZahmJMGarnotelR. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J. 2008;416(2):255–261.
74.
PalumboRDe MarchisFPusterlaTContiAAlessioMBianchiME. Src family kinases are necessary for cell migration induced by extracellular HMGB1. J Leukoc Biol. 2009;86(3):617–623.
75.
KimWKSonYSLeeJH. Macrobenthic community at type and age-different artificial reefs located along the Korean coast of the East Sea. J Environ Biol. 2008;29(4):501–505.
76.
ReddyMALiSLSaharS. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem. 2006;281(19):13685–13693.
77.
HudsonBIKaleaAZDel Mar ArrieroM. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008;283(49):34457–34468.
78.
FehrenbachHWeiskirchenRKasperMGressnerAM. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology. 2001;34(5):943–952.
79.
YoshidaTYamagishiSNakamuraK. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia. 2006;49(12):3094–3099.
80.
BrettJSchmidtAMYanSD. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143(6):1699–1712.
81.
AlexiouPChatzopoulouMPegklidouKDemopoulosVJ. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem. 2010;17(21):2232–2252.
82.
BastaG.Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9–21.
83.
YonekuraHYamamotoYSakuraiSWatanabeTYamamotoH. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci. 2005;97(3):305–311.
84.
YanXXLuLPengWH. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. 2009;205(2):544–548.
85.
UrbonaviciuteVVollRE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med. 2011;270(4):309–318.
86.
YounJHOhYJKimESChoiJEShinJS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol. 2008;180(7):5067–5074.
87.
CampanaLBosurgiLBianchiMEManfrediAARovere-QueriniP. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol. 2009;86(3):609–615.
88.
AbeyamaKSternDMItoY. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115(5):1267–1274.
89.
ItoTKawaharaKNakamuraT. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5(1):109–116.
LegrandMKlijnEPayenDInceC. The response of the host microcirculation to bacterial sepsis: does the pathogen matter?J Mol Med (Berl). 2010;88(2):127–133.
92.
YangHOchaniMLiJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101(1):296–301.
93.
LutterlohECOpalSMPittmanDD. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007;11(6):R122.
HuangWLiuYLiL. HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation. 2012;35(1):350–362.
96.
FiuzaCBustinMTalwarS. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7):2652–2660.
97.
CatezFYangHTraceyKJReevesRMisteliTBustinM. Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol Cell Biol. 2004;24(10):4321–4328.
98.
CalogeroSGrassiFAguzziA. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 1999;22(3):276–280.
99.
LangeSSVasquezKM. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog. 2009;48(7):571–580.
100.
KrynetskaiaNXieHVuceticSObradovicZKrynetskiyE. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol. 2008;73(1):260–269.
101.
LangeSSMitchellDLVasquezKM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci U S A. 2008;105(30):10320–10325.
102.
PrasadRLiuYDeterdingLJ. HMGB1 is a cofactor in mammalian base excision repair. Mol Cell. 2007;27(5):829–841.
103.
YuanFGuLGuoSWangCLiGM. Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem. 2004;279(20):20935–20940.
104.
StrosMChernyDJovinTM. HMG1 protein stimulates DNA end joining by promoting association of DNA molecules via their ends. Eur J Biochem. 2000;267(13):4088–4097.
105.
van GentDCHiomKPaullTTGellertM. Stimulation of V(D)J cleavage by high mobility group proteins. EMBO J. 1997;16(10):2665–2670.
106.
GuBZhuWG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci. 2012;8(5):672–684.
107.
JayaramanLMoorthyNCMurthyKGManleyJLBustinMPrivesC. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998;12(4):462–472.
108.
McKinneyKPrivesC. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol. 2002;22(19):6797–6808.
109.
MerenmiesJPihlaskariRLaitinenJWartiovaaraJRauvalaH.30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem. 1991;266(25):16722–16729.
110.
EllermanJEBrownCKde VeraM. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836–2848.
111.
YuWKimJOssowskiL. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997;137(3):767–777.
112.
TaguchiABloodDCdel ToroG. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354–360.
113.
RauvalaHHuttunenHJFagesC. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol. 2000;19(5):377–387.
114.
ParkkinenJRauloEMerenmiesJ. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem. 1993;268(26):19726–19738.
115.
ParkkinenJRauvalaH.Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem. 1991;266(25):16730–16735.
116.
TreutigerCJMullinsGEJohanssonAS. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003;254(4):375–385.
NagataniGNomotoMTakanoH. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res. 2001;61(4):1592–1597.
119.
TakadaMHirataKAjikiTSuzukiYKurodaY. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology. 2004;51(58):928–930.
120.
PoserIBosserhoffAK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol. 2004;19(1):173–188.
121.
PoserIGolobMBuettnerRBosserhoffAK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol. 2003;23(8):2991–2998.
122.
GolobMBuettnerRBosserhoffAK. Characterization of a transcription factor binding site, specifically activating MIA transcription in melanoma. J Invest Dermatol. 2000;115(1):42–47.
123.
JacobKWachFHolzapfelU. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res. 1998;8(3):211–219.
124.
VolpKBrezniceanuMLBosserS. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55(2):234–242.
125.
KuniyasuHChiharaYKondoH. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 2003;104(6):722–727.
126.
KuniyasuHYanoSSasakiTSasahiraTSoneSOhmoriH. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol. 2005;166(3):751–760.
127.
BalasubramaniMDayBWSchoenREGetzenbergRH. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res. 2006;66(2):763–769.
128.
SasahiraTAkamaYFujiiKKuniyasuH. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005;446(4):411–415.
129.
LotzeMTDeMarcoRA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003;4(12):1405–1409.
130.
BrezniceanuMLVolpKBosserS. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17(10):1295–1297.
131.
SasahiraTKiritaTOueN. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci. 2008;99(9):1806–1812.
132.
AbdulahadDAWestraJBijzetJLimburgPCKallenbergCGBijlM. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(3):R71.
133.
TianJAvalosAMMaoSY. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–496.
134.
LiDWangHXiangJJ. Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep. 2010;24(2):457–463.
135.
HayashiANagafuchiHItoIHirotaKYoshidaMOzakiS. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol. 2009;19(3):283–292.
136.
AnderssonUErlandsson-HarrisH. HMGB1 is a potent trigger of arthritis. J Intern Med. 2004;255(3):344–350.
137.
PisetskyDSErlandsson-HarrisHAnderssonU. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008;10(3):209.
138.
TaniguchiNKawaharaKYoneK. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48(4):971–981.
139.
AyerLMSenecalJLMartinLDixonGHFritzlerMJ. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol. 1994;21(11):2071–2075.
140.
YoshizakiAKomuraKIwataY. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol. 2009;29(2):180–189.
141.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
142.
KalininaNAgrotisAAntropovaY. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24(12):2320–2325.
143.
AnderssonUWangHPalmbladK. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192(4):565–570.
144.
PortoAPalumboRPieroniM. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006;20(14):2565–2566.
145.
YangDChenQYangHTraceyKJBustinMOppenheimJJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol. 2007;81(1):59–66.
146.
DumitriuIEBianchiMEBacciMManfrediAARovere-QueriniP. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol. 2007;81(1):84–91.
147.
KanellakisPAgrotisAKyawTS. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(2):313–319.
148.
MarczinNBundyREHoareGSYacoubM. Redox regulation following cardiac ischemia and reperfusion. Coron Artery Dis. 2003;14(2):123–133.
149.
AndrassyMVolzHCIgweJC. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117(25):3216–3226.
150.
TzengHPFanJVallejoJG. Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol. 2008;294(3):H1490–H1496.
151.
HagiwaraSIwasakaHUchinoTNoguchiT. High mobility group box 1 induces a negative inotropic effect on the left ventricle in an isolated rat heart model of septic shock: a pilot study. Circ J. 2008;72(6):1012–1017.
152.
LimanaFGermaniAZacheoA. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res. 2005;97(8):e73–e83.
153.
LimanaFEspositoGD'ArcangeloD. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One. 2011;6(6):e19845.
154.
KitaharaTTakeishiYHaradaM. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res. 2008;80(1):40–46.
155.
RossiniAZacheoAMociniD. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol. 2008;44(4):683–693.
156.
ChavakisEHainAVinciM. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res. 2007;100(2):204–212.
157.
BiscettiFStrafaceGDe CristofaroR. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes. 2010;59(6):1496–1505.
158.
AbarbanellAMHartleyJAHerrmannJL. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery. 2011;149(3):329–335.
159.
HuXJiangHCuiBXuCLuZHeB. Preconditioning with high mobility group box 1 protein protects against myocardial ischemia-reperfusion injury. Int J Cardiol. 2010;145(1):111–112.
160.
KohnoTAnzaiTNaitoK. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res. 2009;81(3):565–573.
161.
GoldsteinRSGallowitsch-PuertaMYangL. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock. 2006;25(6):571–574.
162.
AndrassyMVolzHCRiedleN. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med. 2011;270(3):245–253.
163.
CirilloPGiallauriaFPacileoM. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. J Card Fail. 2009;15(4):362–367.
164.
GiallauriaFCirilloPLucciR. Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis. 2010;208(1):280–284.
165.
SorensenMVPedersenSMogelvangRSkov-JensenJFlyvbjergA. Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2011;4(3):281–286.
166.
GiallauriaFCirilloPLucciR. Effects of exercise-based cardiac rehabilitation on high mobility group box-1 levels after acute myocardial infarction: rationale and design. J Cardiovasc Med. 2009;10(8):659–663.
167.
GiallauriaFCirilloPD'AgostinoM. Effects of exercise training on high-mobility group box-1 levels after acute myocardial infarction. J Card Fail. 2011;17(2):108–114.
